Kerry McCarthy

The UK has a resilient food supply chain and is equipped to deal with situations with the potential to cause disruption. Food security is built on supply from diverse sources, strong domestic production as well as imports through stable trade routes. Whilst the UK has a high degree of food security, the UK Food Security Report 2024 shows that food security cannot be taken for granted. Climate and geopolitical volatility have weakened aspects of food supply stability since 2021, although food availability or the quantity of food available to the UK has been maintained thanks to continued resilience in food production and the global trading system. Defra works with industry and across Government to monitor risks that may arise. This includes extensive, regular and ongoing engagement in preparedness for, and response to, issues with the potential to cause disruption.

The revised Environmental Improvement Plan, published 1 December 2025, includes a commitment to reform UK REACH, to enable protections that address chemical pollution to be applied more quickly, efficiently and in a way that is more aligned with our closest trading partners, especially the EU, by December 2028.

The Stockholm Convention on Persistent Organic Pollutants (POPs), to which the UK is party, requires that waste containing POPs above certain thresholds be destroyed, rather than landfilled. Research by the Environment Agency (EA) in 2021 revealed that waste upholstered domestic seating contains POP flame retardant chemicals above the legal thresholds. Local authorities are responsible for managing this waste in accordance with legal requirements, and they would hold information on their costs of doing so.

The UK recognises the urgency of taking action to ensure that UK consumption of forest risk commodities is not driving deforestation.

The Government is carefully considering the best regulatory approach to address deforestation in UK supply chains; we will set out this approach in due course. We need to balance a range of factors, including the broader policy landscape and relevant international frameworks.

We recognise the urgency of taking action to ensure that UK consumption of forest risk commodities is not driving deforestation. We also recognise that this sense of urgency and need for clarity is shared by business.

This Government believes it is at its best when it works in partnership with business, civil society, trade unions, and communities.

We will set out our approach to address deforestation in the UK’s supply chains in due course and engage with stakeholders on this approach.

The Health and Safety Executive (HSE) has recognised the risks to textile workers who routinely handle finished fabrics, including those treated with fire-resistant finishes. HSE has produced a specific guidance page on its website which covers both the initial manufacture and any secondary processing of finished fabrics (such as upholstery). The guidance page can be found here: https://www.hse.gov.uk/textiles/fabric-finishes.htm

The Control of Substances Hazardous to Health Regulations 2002 (COSHH) outline specific duties on employers to protect workers from harmful substances, such as foams and flame retardants, which may be contained in soft furnishings such as mattresses and sofas. HSE provides practical advice and guidance on the basics of COSHH, completing COSHH assessments and links to industry specific information and guidance to prevent and control workplace exposure to harmful substances at http://www.hse.gov.uk/coshh(opens in a new tab).

The waste and recycling industry recognises the potential risks to workers from disposing of waste upholstered furniture (WUDs) containing fire retardants. The current Environment Agency guidance is available here - Manage waste upholstered domestic seating containing POPs - GOV.UK. HSE scientists have visited a number of sites processing this waste to sample possible worker exposures. The Waste Industry Safety and Health Forum (WISH) is currently preparing sector health and safety guidance based on this.

DWP’s digital Universal Credit (UC) application pathway uses automated prompts to ask claimants proactively whether any children are disabled. Where this is confirmed, the system guides them through the relevant eligibility criteria, helping ensure the correct addition is applied at the point of claim. This is currently the primary mechanism to identify likely eligibility and raise claimant awareness at the point of claiming UC.

Claimants are informed through routine DWP communications of the importance of reporting any changes of circumstances. This would include where a child becomes disabled after the initial claim or a disabled child joins the household.

DWP maintains extensive internal and public‑facing guidance concerning the Disabled Child Addition. This guidance is refreshed and reviewed regularly and enables DWP Staff to answer customer queries, as well as customers to self-serve via gov.uk.

The average time to process a Personal Independence Payment (PIP) appeal for all PIP appeals registered in the Bristol East constituency since PIP was introduced can be found below.

Source: PIP Administrative Data

Notes:

• The appeal processing time is calculated as the time between the date of appeal registration and date of appeal clearance.
• Times have been rounded to the nearest week.
• Figures include appeals related to initial decisions (including new claims and DLA reassessments), award reviews and changes of circumstance.
• Figures include time taken by His Majesty’s Courts and Tribunals Service (HMCTS) to clear the case.

DWP’s digital application process uses automated prompts to identify where a claimant has a disabled child and guides them through the relevant eligibility criteria, helping ensure the correct addition is applied at the point of claim. This is currently the primary mechanism to identify likely eligibility and raise claimant awareness at the point of claiming UC.

The Department keeps all aspects of Universal Credit under review to ensure the system remains responsive, accurate and efficient. Our processes are dynamic, and we routinely explore opportunities to introduce further automation to streamline the process and further improve the claimant experience, including where claims to other benefits have been made.

The Health and Safety Executive (HSE) provides readily accessible guidance to all employers on the Working Time Regulations 1998 on its website and is responsible for the enforcement of the maximum weekly working time limit, night work limits, and health assessments for night work. Issues relating to rest periods and time off are a matter for an Employment Tribunal.

It is the duty of each individual NHS trust, or employing organisation, to ensure they have systems in place to comply with these regulations. HSE responds to all concerns related to working time in a proportionate way, which may include activities such as stakeholder engagement, inspections and investigations, and taking robust enforcement action if employers are not complying with legal requirements.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based guidance for the National Health Service on best practice in the care and management of patients with specific conditions based on an assessment of clinical and cost effectiveness.

NICE has published a guideline on the diagnosis and management of endometriosis that includes recommendations on the use of ablation. The analysis underpinning NICE’s recommendations can be found in the full guideline that is available at the following link:

https://www.nice.org.uk/guidance/ng73/evidence/full-guideline-pdf-4550371315

NICE is working with NHS systems to ensure adoption of this best practice endometriosis care, including access to approved medicines.

The Government will consider long-term conditions for future waves of modern service frameworks (MSFs), including respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is potential for rapid and significant improvements in quality of care and productivity. After the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme. There has not, therefore, been a specific assessment made in relation to National Health Service provision in the Bristol East constituency.

The Department recognises that the cost of travel should not be a barrier to cancer treatment. NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of local communities are met, including providing support for travel.

The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or Personal Independence Payment.

General practitioners (GPs) and nurses are responsible for ensuring their own clinical knowledge, including on endometriosis and women’s health issues in general, remains up to date and for identifying learning needs as part of their continuing professional development, within their scope of practice.

All United Kingdom registered doctors are expected to meet the professional standards set out in the General Medical Council’s (GMC’s) Good Medical Practice. The training curriculum for postgraduate trainee doctors is set by the Royal College of General Practitioners (RCGP) and has to meet the standards set by the GMC.

The GMC has introduced the Medical Licensing Assessment to encourage a better understanding of common women’s health problems among all doctors as they start their careers in the UK. The content map for this assessment includes several topics relating to women’s health including menstrual problems, endometriosis, menopause, and urinary incontinence. This will encourage a better understanding of common women’s health problems among all doctors as they start their careers in the UK. Endometriosis is also included in the core curriculum for trainee GPs, and for obstetricians and gynaecologists. The British Medical Journal and RCGP offer online courses on endometriosis designed for healthcare professionals, including practice nurses.

In November 2024, the National Institute for Health and Care Excellence (NICE) updated their guideline on endometriosis which makes firmer recommendations for healthcare professionals on referral and investigations for women with suspected diagnosis, which is available at the following link:

https://www.nice.org.uk/guidance/NG73

GPs and primary care networks have access to a regional Primary Care Training Hub, which brings together education and training resources from National Health Service organisations, community providers, as well as local authorities. Training hubs are usually run by a clinical leader and a manager supported by a network of primary care staff with education and training professionals based in the community. They work closely with primary care networks and integrated care systems to support workforce priorities and tackle health inequalities to help meet patient and population demand. Training hubs support all clinical staff, including nurses, to maintain their continuing professional development when new guidance, such as that from NICE, becomes available.

The role of the Medicines and Healthcare products Regulatory Agency (MHRA) is to monitor all incidents that are reported to us, making sure that these incidents are investigated fully and that any necessary action is taken. The poly implant prothèse (PIP) issue was a result of the use of a non-approved silicone in the production of the breast implants and fragile shells. Not all PIP implants manufactured during the affected period used industrial-grade silicone or had more fragile shells. As a result, rupture rates vary depending on the batch received and early rupture typically occurs within the first five to 10 years. Due to the overall fraudulent activity, we do not know how many fall into this category.

We worked with the National Health Service and other health partners to ensure the issue was properly investigated. It is important to note that while PIP implants are associated with a higher risk of rupture, leading to symptoms such as tenderness or swollen lymph glands, there is no evidence linking ruptured PIP implants to serious long-term health issues. The PIP breast implants were withdrawn from the United Kingdom in 2010, and two independent reviews have identified lessons learned, the Howe Review (2012) and the Keogh Review (2013), with further information available on both, respectively, at the following two links:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/216537/dh_134043.pdf

https://www.gov.uk/government/publications/review-of-the-regulation-of-cosmetic-interventions

One of the concerning issues for women with breast implants at the time of PIP was that women didn’t know they had PIP breast implants. It is estimated that approximately 47,000 British women had PIP implants fitted. We are unable to provide the granularity for individual constituencies, although further information is available at the following link:

https://www.nhs.uk/conditions/pip-implants/

However, please note that any PIP implants still in place have now exceeded 15 years in situ, which is the upper end of the 10 to 15 year typical life expectancy of a breast implant. As with any medical device reaching the end of its expected lifespan, clinical decisions regarding removal or replacement should be made on an individual basis in discussion between the doctor and the individual involved.

The health system has enacted important changes since the publication of reviews focused on PIP implants. As a result of the Keogh Review, since 2016 the Breast and Cosmetic Implant Registry collects data on all types of breast implant and removal surgery in England and Scotland, which aims to help detect emerging safety issues and trace patients if necessary.

As part of MHRA’s regulatory reform program, we are intending to also improve the traceability of medical devices through the introduction of Unique Device Identifiers (UDI) which will help identify individual medical devices and who manufactured the device or placed it on the market.